Reviews
Provider reviews
Everyone else reviews these companies on price and delivery speed. We ask four questions instead: what regulatory category is the thing in the vial, has the molecule been tested in a human for the use it is sold for, do the marketing claims survive the trials, and who is actually licensed to fill the prescription.
No scores and no stars. Companies we have a paid relationship with are listed first, and we say so here rather than marking individual rows; everyone else follows, and within both groups the order is alphabetical. Being a partner changes where a company sits, never a single number printed beside it. Our editorial policy sets out how a claim is checked; our disclosure sets out the one thing commission is never allowed to reach.
Published
Every review on this site
Showing 111 of 111 reviews
Belle offers GLP-1s and longevity injections. We examine its sleep, recovery and energy claims, public pharmacy disclosures and pricing terms.
Bodybuilding Health+ names two physicians and four pharmacies, then says full results develop in two to three months. The trials ran 68 and 72 weeks.
Collective review: medication and membership costs, state eligibility, and the observational evidence behind its weight-loss calculator.
CoreAge Rx’s peptide claims, advertised starting prices, prescribing arrangements and refund limits, with public sources checked in October 2026.
DirectMeds’ peptide care, public offer, pharmacy disclosures and refund limits, with current claims separated from older review observations.
DudeMeds argues against compounded testosterone in detail, then sells compounded semaglutide described as an Ozempic generic and an FDA-approved medication.
Eden sells approved Wegovy at $1,695 and compounded sermorelin at $126 from the same cart. The evidence behind those two numbers is not comparable.
Embody sells "GLP-1 Injections" from $79/month and never writes the words semaglutide or tirzepatide anywhere on its homepage.
Enhance MD prints the real interval beside the label: its "12-month" NAD+ plan is billed every 48 weeks, and its "1-month" plan every four.
EverPrime offers GLP-1s and longevity treatments. Our review examines selected claims, pharmacy disclosures, optional membership and unclear fees.
Found credits "up to 15-20% weight loss" to Wegovy and Zepbound by name, not to its compounded products — and publishes no state list at all.
Gala's $179/month is a yearly-prepay rate, and it says so. The standing price is $299, billed every four weeks, so a year holds thirteen charges.
HealthRX names STEP 1 and SURMOUNT-1, prints no weight-loss figure for its compounded GLP-1s, and says the trials tested a different product.
HumeCare+ says its patients average 21.5% weight loss in 10 months — more than either GLP-1 trial found. The number is its own, and unpublished.
Live Vital publishes 156 PubMed-keyed study summaries and links none of them from any product page. Eleven of its fourteen products cite nothing at all.
Luvo Health attaches no number to its weight-loss timeline. Its longevity program names five products and promises five benefits none of them is tied to.
MangoRx names its pharmacy — Epiq Scripts — which almost nobody does. Its Terms then make you waive the right to any other, while its FAQ says you have it.
MEDGm's intake told us our success probability was 100% before any clinician looked, and its 'clinical results' are self-reported. The trials, checked.
Our September MyDrHank source review, with October buyer guidance. Current offer terms and product-page claims need confirmation.
Oak sells sermorelin, tesamorelin, NAD+ and glutathione with no product page at all. The only thing it publishes about each is a name and a price.
RNK Health promises effortless weight loss and cravings that vanish instantly. Its 'one price' on peptides turns out to be a six-month plan.
RxSpan MD lists compounded semaglutide at $249 and never says whether that is a month, a quarter or a single vial. It also names its physician.
Sesame's Wegovy pill claim sits under its own trial at 14%. One variant of its weight-loss page says 25%, with no drug, dose or source named.
Shed review: compare the documented prices, GLP-1 trial claims, sermorelin evidence and pharmacy disclosures before choosing treatment.
SkinnyRx’s current peptide catalog, introductory pricing and evidence limits, with its dated FDA warning-letter history clearly separated.
SnagRx promises "up to 15% of your body weight (1-2lbs per week)". STEP-1 averaged about 0.23% a week — a quarter to a half of that rate.
FDA wrote to Sprout Health about a single sentence claiming GLP-1s are FDA-approved. The sentence is gone; the letter is still open.
Strut's NAD+ page calls the coenzyme "a peptide that signals your own pituitary gland". No trial tests what its flagship peptide promises.
Wellorithm's quiz tells you to expect 3.75 to 4.17 pounds a week and a ten-week finish. The landmark trial averaged under half a pound a week.
WellMedr now uses Welludr. We examine its GLP-1 and NAD+ mixture claims, named pharmacy, public starting prices and 21-day billing option.
Willow names five pharmacies and prints a price for every dose. It also says stopping is fine and muscle loss isn't a concern. The trials disagree.
yourEra sells compounded GLP-1 from $79 a month and advertises a -13.6% average member loss. It names its pharmacies; the figure has no method.
1st Optimal publishes its 503A pharmacy by name and address — and names only two peptide molecules anywhere on its site.
AgelessRx sponsors ten registered trials and published PEARL. Its primary endpoint was null — and the biggest number on the page is a customer survey.
AHBARx writes "may support" where others write "supports". The hedging is real and it does not change what has been tested.
Alan's low GLP-1 headline is a buy-one-get-one-free promotion on a two-month prepay. Its longer plans are quoted higher per month, not lower.
Alinwell sells four peptides from $199 a month. Its lab certificates cover only its GLP-1s, and two of its peptides carry two prices on one site.
Andrew Meds sells two peptide products and asserts no outcome for either. Its signup screens are a different matter.
Auren Rx names its pharmacy and prints FDA's own compounding disclaimer on every page — then sells collagen, sleep and clarity the trials do not support.
Believe Health sells four peptides from $199 a month at clear prices. It publishes no lab result, names no pharmacy and lists only a Wyoming mailbox.
Bliv quotes four different entry prices on a single page and names its pharmacy only inside the telehealth consent form. Here is what each figure buys.
bmiMD sermorelin sleep and muscle claims, formulation evidence, public price ladder and pharmacy questions.
BreezeMeds review: named pharmacies, unclear product details and missing cancellation terms. What the clinical evidence can and cannot tell you.
CareBareRX is the only seller here that cites a trial on a product page and quotes it accurately. Four of its "starting at" prices are refuted by its catalog.
Clume sells NAD+ and sermorelin as "Molecular Cellular Optimization" — and misspells the drug on the card.
Defy is a real Tampa clinic with a named medical director. Its Peptide Therapy page names no peptide, and it calls sermorelin FDA-approved.
Edessa publishes an 18% average weight loss, a 93% maintenance rate and a 6.5-inch waist reduction under a "clinical data" heading. None carries a source.
We completed Eviora MD's signup — twenty-eight screens including date of birth and shipping address — and were never shown a price at any step.
Fella sources its weight-loss average to its own members, not a trial. Its quiz then quotes a higher average — and no GLP-1 price appears anywhere.
GOAL MD publishes flat-dose pricing and prepaid totals. Check the dispensing pharmacy and what its FDA-monitored wording actually establishes.
Goldspan has 29 product pages. One of them tells tirzepatide buyers they are getting semaglutide.
He & She MD barely claims anything about efficacy, and its one outcome figure is its own self-reported data. The pricing is where the real problem sits.
Henry Meds offers multiple GLP-1 formats. Compare the actual formulation, pharmacy, evidence and payment terms before choosing treatment.
Hers GLP-1 options, product-specific evidence, reproductive-health questions and separate care membership costs.
Hims current GLP-1 products, clinical evidence, separate membership charges and dated FDA marketing history.
Hone sells compounded PT-141 to men at $130/mo. The FDA label for the approved version says it is not indicated in men, or to enhance performance.
Idgie now names a partner pharmacy and advertises no membership fee. Check product-specific availability, refund rules and the terms for your actual plan.
Invigor names all five compounding pharmacies it uses — a rare disclosure. Its GLP-1 pages never once say semaglutide or tirzepatide.
Ivim’s membership, named pharmacies, published observational outcomes and cancellation terms, with a clear distinction between completers and all starters.
Joi + Blokes sells sermorelin and VIP with numbers attached — 5-10% body fat, 10% lean muscle. No trial in either literature reports them.
Lean Meds says sermorelin restores energy, recovery and sleep, under a clinical-research banner. The 19 sermorelin trials measured none of those.
LifeMD GLP-1 care, clinical evidence, insurance assistance and the limits of its weight-loss refund guarantee.
Lighter You now names sermorelin and NAD+ and prices them. Its own TidesRx pages price the same three products lower than its home page does.
Longevixx sells tesamorelin, sermorelin, NAD+ and PT-141 beside its GLP-1 plans. It publishes no certificate of analysis and names no pharmacy.
LumiMeds advertises three low entry rates and publishes no rung behind them. Its membership terms are non-cancelable and non-refundable mid-term.
Not one of Magnolia's 24 product pages says what the product does. The category label does it instead.
Marek Health names seven pharmacies. How its PT-141 and tadalafil offer differs from the approved indication and earlier male research.
Maximus fixed the four claims FDA cited in June 2026. Its newest peptide rests on an unpublished, uncontrolled study the company ran on itself.
Mochi separates membership and medication. Review current dose-dependent pricing, pharmacy choice and the evidence for compounded semaglutide.
Mondae describes its three peptides in one line each. One names a mechanism trials measured; the other two name nothing a trial could.
NEUVÉ publishes eleven priced peptide protocols and says they are compounded by "503A and 503B certified" pharmacies. No such certification exists.
New Wave Health names its company and address. Its product pages put STEP 1's 68-week and SURMOUNT-1's 72-week averages at month six.
Nex Gen names Manifest Pharmacy, which few sellers do. It also badges every product "503A accredited pharmacies" — a designation that does not exist.
No BS RX names all four pharmacies that might fill your prescription, with addresses and phone numbers, and states the compounding tier on every plan.
Noom Med’s current bundled plans, quarterly billing, self-reported results and the distinction between app engagement and proven treatment benefit.
Nova says injected NAD+ restores cellular NAD+ and is the strongest delivery route. No trial has measured either. Its peptide claims, checked.
Novo Nordisk's direct pharmacy sells approved semaglutide with published NDCs and phase 3 evidence. It also calls itself FDA-approved, which no pharmacy is.
OrderlyMeds names pharmacy partners and distinguishes starter pricing. Review what those disclosures establish about care and compounded GLP-1s.
Oria's semaglutide page reads STEP 1 carefully and prices every plan. Its homepage card promises a 15–20% average loss that trial did not produce.
Pallas names six pharmacies with phone numbers and says NAD+ research "is still developing" — then bills every four weeks: thirteen charges a year.
Peak Wellness names the pharmacy that compounds its GLP-1s, which is rare and useful. It also turns a trial's best-case result into an average.
PeptidesRx prices, included services and pharmacy disclosures reviewed, with the difference between peptide claims and clinical evidence.
Polly names its 503A pharmacies and covers all 50 states. Its treatment grid shows no prices, and the visit asks for your email before any figure.
Prime Doctor RX publishes no weight-loss percentage, no timeline and no before-and-after. Its clinical copy is a series of refusals to promise anything.
Regenics sells 12 peptides to members only. None is cleared for compounding: 11 were on FDA's Category 2 list until April 2026, and ipamorelin still is.
Rehydra+ still lists BPC-157, KPV and MOTS-c on its site. Every one of those pages now redirects to a login. Here is what it will actually sell you.
Compare Remedy Meds’ member-results claims, year-long refund conditions and prescribing arrangements for compounded GLP-1 care.
Renlo Health attributes its weight-loss figures to STEP 1 and SURMOUNT-1 by name, labels them averages, and publishes no timeline to get wrong.
Ro approved medication options, separate membership terms, paid testimonials and the clinical questions to resolve.
RX Bella cites STEP 1 and SURMOUNT-1 by name, then places their 68- and 72-week results at month six — and credits a diabetes trial for weight maintenance.
Rx Com names its dispensing pharmacy with an address and its clinical network. Its one weight promise, "lose pounds of fat every week", outruns the trials.
Science & Co review: online care, prepaid costs, cancellation terms and the inconsistent numbers in its current weight-loss example.
Our September SexyMD source review, with October buyer guidance. Current offer terms and product-page claims need confirmation.
Solaya publishes a provider number that resolves in the federal registry — and no price for any peptide.
Superior Remedies puts semaglutide's ~15% at month 6. STEP 1 measured it at week 68 — about 15.6 months. It also cites a diabetes trial family.
Synergy Rx sells five different peptides at $275 each and leads with "The Proven Way to lose 15% of your body weight fast" — with nothing cited.
telos rx sells ten peptides and hedges every claim as "studied for". Its BPC-157 FAQ answers the obvious question with "We cannot say that."
The Edit names its pharmacy, its practice and its regulatory category — then markets sermorelin for sleep and NAD+ for focus. The trials say otherwise.
TOM says compounded medications are not FDA-approved and carry additional risks, and names five pharmacies with prices.
Transcend names four pharmacies and publishes the compounded-drug disclaimer on one page — while another page still calls tesofensine a peptide.
Trava says its GLP-1s are “tested in the USA by FDA labs” and calls its lab “FDA approved”. FDA approves no labs, and no test result is published.
Trellis names its pharmacy and names the doctor in charge, license and all. It also sells injectable NAD+ and glutathione on claims no human trial supports.
Trimi cites STEP 1, SURMOUNT-1 and SELECT with their populations, says they tested the branded drug, and names two 503A pharmacies with a license number.
TrimRx compounded and branded pathways, comparative speed claim, pricing differences and conditional weight-loss warranty.
Try Ageless review: compare prices and injectable trial claims with the evidence assessed for its sublingual tirzepatide drops.
Valhalla sells GLP-1 (T) and GLP-1 (S). It never writes tirzepatide or semaglutide in any copy a reader can see, and hides every price behind a login.
VAULT sells ten prescription peptides with published doses — under a Terms of Service that says its products are not intended to treat any disease.
VevaRX says plainly on every peptide page that compounded drugs are not FDA-approved. It names no pharmacy, no clinician and no mailing address.
Vyvron sells sermorelin and NAD+ programs at $189 founding, $229 after. Its site never mentions USP, sterility, potency or a certificate of analysis.
WW Clinic membership commitments, medication charges and the limits of its engagement-based GLP-1 results, separated from drug-trial evidence.
Zealthy medication pathways, evidence limits, bundled versus separate fees and questions to resolve before paying.